Status:
COMPLETED
Phenotype Depression Study
Lead Sponsor:
Emory University
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
21-65 years
Brief Summary
To facilitate the development of a personalized approach to the treatment of patients with major depression, this study is designed to elaborate the clinical and neurobiological phenotype of depressed...
Detailed Description
One hundred and thiry-five patients with major depression diagnosed based on DSM-IV TR criteria between the ages of 21 and 65 (males, females and minorities) will be recruited. Forty-five patients wit...
Eligibility Criteria
Inclusion
- age 21-65 years including males, females and minorities
- diagnosis of DSM-IV major depression or Bipolar I or II with current episode of depression
- HDRS-17 \> 20 and HDRS-24 \> 24
- negative pregnancy test for women of childbearing potential
- not breast feeding
- stable on current dose of psychotropic medication or free from all psychotropic medications for 4 weeks prior to EUH CIN admission (8 weeks for fluoxetine)
- no suicide attempt within six months of screening
Exclusion
- evidence of untreated or poorly controlled endocrine, cardiovascular, pulmonary, hematological, renal, or neurological disease
- history of CNS trauma or active seizure disorder requiring medication unless otherwise approved by principle investigator
- autoimmune or inflammatory disorder of any kind
- chronic infection (e.g. hepatitis B or C or HIV)
- chronic use of agents known to affect the immune system including glucocorticoid therapy within the past 1 year, methotrexate within the past 1 year, chemotherapy of any kind (past or present), immunotherapy of any kind (past or present), aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) (within the past 2 weeks) and statins (within the past 1 month) unless otherwise approved by principle investigator
- hemoglobinopathies (e.g. thalassemia)
- a positive pregnancy test
- organ transplants
- cancer of any type
- a score of \<28 on the Mini Mental Status Exam (MMSE)unless otherwise approved by principle investigator
- meets criteria for schizophrenia (Given overlap of generalized anxiety disorder (GAD) with major depression, GAD will not be exclusionary)
- current eating disorders
- active abuse of alcohol or illicit/prescription drugs within the past year unless otherwise approved by principle investigator.
- MGH-S \>3 unless otherwise approved by principle investigator
- BMI \>40 unless otherwise approved by the principle investigator
- active suicidal intent or plan and a score \>2 on the HDRS suicide item (item #3).
- any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with participating in or completing the protocol
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
279 Patients enrolled
Trial Details
Trial ID
NCT01426997
Start Date
July 1 2010
End Date
May 1 2016
Last Update
June 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Department of Psychiatry and Behavioral Sciences
Atlanta, Georgia, United States, 30322